Nitroxide Therapy for VHL Disease and Renal Clear Cell Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with elevated HIF-2α, such as von Hippel-Lindau disease and renal clear cell carcinoma, are limited in effectiveness, with existing therapies showing low response rates and high resistance, particularly in advanced stages, and there is a need for new molecular therapies to address these conditions.
Innovation Solution
Administration of a stable nitroxide composition, specifically 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol), to reduce HIF-2α levels in subjects with or at risk for conditions related to elevated HIF-2α expression, including VHL disease and RCC, by determining compromised VHL function through genetic or protein level analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (chemotherapy, immunotherapy with IL-2, targeted therapy) are used for RCC and VHL disease, then treatment is provided to patients, but response rates are low and resistance is high
Solution Approach 1:
The patent changes the molecular target parameter from conventional chemotherapy targets to HIF-2α, a transcription factor that is constitutively expressed in VHL disease and RCC. By targeting HIF-2α with nitroxide compounds, the treatment achieves effective reduction of HIF-2α levels and inhibition of tumor growth, overcoming the low response rates and resistance associated with conventional therapies that target different pathways.
2Reliability
If surgical removal is used as primary treatment for RCC, then cancerous tissue is removed, but the treatment is invasive and does not address molecular pathways
Solution Approach 1:
The patent replaces the mechanical surgical removal approach with a molecular therapy approach using nitroxide compounds that target HIF-2α. This substitution provides a non-invasive alternative to surgery by using chemical agents to inhibit tumor growth at the molecular level, thereby controlling cancer without the need for invasive surgical procedures.
3Ease of operation
If no treatment is provided to asymptomatic RCC patients, then quality of life is maintained, but tumor progression occurs and survival rate is low
Solution Approach 1:
The patent enables preliminary treatment of asymptomatic RCC patients by targeting HIF-2α before significant tumor progression occurs. By administering nitroxide compounds that reduce HIF-2α levels, the treatment can be initiated early in the disease course, preventing tumor progression and improving survival outcomes while maintaining the patient's asymptomatic status and quality of life.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of stable nitroxides effectively reduces HIF-2α levels, inhibiting tumor growth and vascular remodeling, thereby providing a therapeutic benefit in treating and preventing the progression of associated conditions like RCC and pulmonary arterial hypertension.
Implementation Method 1
administering an effective amount of a stable nitroxide composition to the subject and thereby reducing the level of HIF-2α in the subject
Data Source
AI summary
The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2α.